Symbicort is a combination inhaler used to control asthma and to maintain airflow in people with chronic obstructive ...

namely maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD). Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the ...

"Previous findings have shown the beneficial effects of combination budesonide and formoterol, i.e. Symbicort, therapy in significantly reducing COPD exacerbations", explained Professor Peter ...

Symbicort was first FDA-approved in 2006 as a treatment for asthma, followed by an extension to its label covering COPD in 2009 ... in a single inhaler. A Viatris spokesperson said: "Viatris ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder ... AstraZeneca’s Symbicort inhaler accounts for most ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.